Skip to content

Efficacy and Safety of AI-Assisted Robot-Assisted Laparoscopic Selective Renal Artery Branch Clamping for Partial Nephrectomy in =T1b Renal Cell Carcinoma: A Prospective Study

Efficacy and Safety of Artificial Intelligence-Assisted Robot-Assisted Laparoscopic Selective Renal Artery Branch Clamping for Partial Nephrectomy in Patients with =T1b Stage Renal Cell Carcinoma: A Prospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112772
Enrollment
Unknown
Registered
2025-11-19
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Selective branch of renal artery occlusion group:By combining preoperative imaging (CT/MRI) with AI technology (Med3D), the tumor-feeding arterial branches can be precisely identified. During the oper
The group with total renal artery occlusion:None

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Participants voluntarily enrolled in the study and signed informed consent forms. 2. Patients with renal carcinoma classified as T stage >= T1b. 3. Patients meeting the indications for partial nephrectomy (PN). 4. Age range: 18 to 80 years. 5. Preoperative renal function within normal limits (serum creatinine <= 1.5 times the upper limit of normal).

Exclusion criteria

Exclusion criteria: 1. Individuals with significant anatomical abnormalities; 2. Patients with solitary kidney, multiple renal tumors, or bilateral renal tumors; 3. Individuals with a history of surgery in the operative region or severe systemic diseases; 4. Patients with an expected survival period of less than one year; 5. Women who are pregnant or lactating; 6. Individuals unable to comply with follow-up protocols.

Design outcomes

Primary

MeasureTime frame
Surgical success rate; intraoperative blood loss; ischemia time;postoperative changes in sGFR;

Secondary

MeasureTime frame
Surgical duration, complication rate, tumor recurrence rate, total GFR change, hospital stay, accuracy verification of AI;

Countries

China

Contacts

Public ContactXinhui Liao

Department of Urology, Shenzhen Second People's Hospital

706751906@qq.com+86 158 1448 8656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026